New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
09 sept. 2024 16h16 HE
|
Treos Bio Corp.
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for...
Peptide Therapeutics Market Forecast to 2028: Projected to Grow by $17.85 Billion, Driven by a Strong Pipeline and Favorable Reimbursement Policies
26 août 2024 07h56 HE
|
Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "Global Peptide Therapeutics Market 2024-2028" report has been added to ResearchAndMarkets.com's offering.The peptide therapeutics market is forecasted...
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
16 juil. 2024 07h30 HE
|
Evaxion Biotech
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art...
Global Custom Antibody (mAbs, pAbs, rAbs) Market Research 2024-2030: Service (Development, Purification, Fragmentation, Labeling), Source (Rabbit, Mice), Application (Research, Therapeutics)
19 juin 2024 10h01 HE
|
Research and Markets
Dublin, June 19, 2024 (GLOBE NEWSWIRE) -- The "Global Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice),...
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
03 juin 2024 07h00 HE
|
Treos Bio Corp.
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
06 mai 2024 08h00 HE
|
Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
02 mai 2024 06h30 HE
|
Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas
25 avr. 2024 05h00 HE
|
PEP-Therapy
Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patientsdans la phase Ib de l’essai clinique évaluant PEP-010dans les cancers de l’ovaire et du pancréas ...
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
25 avr. 2024 05h00 HE
|
PEP-Therapy
Press release PEP-Therapy and Institut Curie Announce First Patients Dosedin Phase Ib Clinical Trial Evaluating PEP-010in Ovarian and Pancreatic Cancers Paris (France), April 25, 2024 – PEP-Therapy,...
Peptide Therapeutics Analysis Report 2024 - Global Forecast to 2030 Featuring Eli Lilly and Co, Pfizer, Amgen, Takeda, AstraZeneca, Teva, Sanofi, F. Hoffmann-La Roche, Novartis, Novo Nordisk
22 avr. 2024 04h14 HE
|
Research and Markets
Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...